BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Murdaca G, Negrini S, Pellecchio M, Greco M, Schiavi C, Giusti F, Puppo F. Update upon the infection risk in patients receiving TNF alpha inhibitors. Expert Opinion on Drug Safety 2019;18:219-29. [DOI: 10.1080/14740338.2019.1577817] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Said JT, Elman SA, Merola JF. Evaluating safety and compatibility of anti-tumor necrosis factor therapy in patients with connective tissue disorders. Ann Transl Med 2021;9:430. [PMID: 33842651 DOI: 10.21037/atm-20-5552] [Reference Citation Analysis]
2 Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Front Med 2022;9:897936. [DOI: 10.3389/fmed.2022.897936] [Reference Citation Analysis]
3 Iwahashi C, Ono H, Haruta M, Minami T, Mashimo H, Shimojo H, Ohguro N. New onset or exacerbation of uveitis with infliximab: paradoxical effects? BMJ Open Ophthalmol 2019;4:e000250. [PMID: 31355342 DOI: 10.1136/bmjophth-2018-000250] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Taylor PC, Atzeni F, Balsa A, Gossec L, Müller-Ladner U, Pope J. The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. J Clin Med 2021;10:509. [PMID: 33535498 DOI: 10.3390/jcm10030509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Huang PY, Chang LS, Guo MM, Kuo HC. Successful treatment in a child with enthesitis-related arthritis involving the sternoclavicular joint: a case report. BMC Pediatr 2019;19:373. [PMID: 31647009 DOI: 10.1186/s12887-019-1770-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Sun L, Hou Y, Zhang L, Liu J, Li L, Wang Z, Yu X, Zhang M, Liu X, Zhao Y, Zheng W. Effectiveness and safety of low-dose interferon alpha-2a treatment in Behçet’s Syndrome with refractory vascular or neurological involvement: a case series. Therapeutic Advances in Chronic Disease 2022;13:204062232211112. [DOI: 10.1177/20406223221111285] [Reference Citation Analysis]
7 Lubrano E, Scriffignano S, Perrotta FM. TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis. Expert Rev Clin Immunol 2019;15:1303-12. [PMID: 31652079 DOI: 10.1080/1744666X.2020.1685382] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
8 Lurain K, Ramaswami R, Yarchoan R, Uldrick TS. Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. Curr HIV/AIDS Rep 2020;17:547-56. [PMID: 32827111 DOI: 10.1007/s11904-020-00525-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kapniari E, Papadimitriou P, Dalamaga M, Makavos G, Piaserico S, Egeberg A, Ikonomidis I, Papadavid E. Investigating the Link between Psoriasis and Cardiovascular Disease: Current Evidence, Therapeutic Implications and Perspectives. CVP 2020;18:592-609. [DOI: 10.2174/1570161118666200523154318] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Fidan S, Capkın E, Arıca DA, Durak S, Okatan IE. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy. Int J Rheum Dis 2021;24:254-9. [PMID: 33244900 DOI: 10.1111/1756-185X.14034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Santoleri F, Romagnoli A, Costantini A. Adalimumab and etanercept adherence, persistence and switch in the treatment of psoriatic arthritis: 10-year real-life analysis. Expert Opinion on Drug Safety 2020;19:93-7. [DOI: 10.1080/14740338.2020.1681396] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Mercogliano MF, Bruni S, Mauro F, Elizalde PV, Schillaci R. Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy. Cancers (Basel) 2021;13:564. [PMID: 33540543 DOI: 10.3390/cancers13030564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Czaja AJ. Advancing Biologic Therapy for Refractory Autoimmune Hepatitis. Dig Dis Sci 2022. [PMID: 35147819 DOI: 10.1007/s10620-021-07378-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Chaer FGG, de Lucena Valim JM, Reis RC, Klautau GB, de Souza BDB. Use of biologic agents and risk of tuberculosis in Brazil, a tuberculosis high-burden country. Drugs Context 2020;9:212598. [PMID: 32788921 DOI: 10.7573/dic.212598] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Alshahrani MY, Alfaifi M, Al Shahrani M, Alshahrani AS, Alkhathami AG, Dera AA, Ahmad I, Wahab S, Beg MMA, Hakamy A, Hamid ME. Increased mRNA expression of key cytokines among suspected cases of Pneumocystis jirovecii infection. BMC Infect Dis 2021;21:28. [PMID: 33413198 DOI: 10.1186/s12879-020-05729-6] [Reference Citation Analysis]
16 Soós B, Fagyas M, Horváth Á, Végh E, Pusztai A, Czókolyová M, Csongrádi A, Hamar A, Pethő Z, Bodnár N, Kerekes G, Hodosi K, Szekanecz É, Szamosi S, Szántó S, Szűcs G, Papp Z, Szekanecz Z. Angiotensin Converting Enzyme Activity in Anti-TNF-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients. Front Med (Lausanne) 2021;8:785744. [PMID: 35155468 DOI: 10.3389/fmed.2021.785744] [Reference Citation Analysis]
17 Mohamad HE, Asker ME, Keshawy MM, Abdel Aal SM, Mahmoud YK. Infliximab ameliorates tumor necrosis factor-alpha exacerbated renal insulin resistance induced in rats by regulating insulin signaling pathway. Eur J Pharmacol 2020;872:172959. [PMID: 32004528 DOI: 10.1016/j.ejphar.2020.172959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Yeh H, Wu RC, Tsai WS, Kuo CJ, Su MY, Chiu CT, Le PH. Systemic lupus erythematosus complicated by Crohn's disease with rectovaginal fistula. BMC Gastroenterol 2021;21:206. [PMID: 33964869 DOI: 10.1186/s12876-021-01801-w] [Reference Citation Analysis]
19 Hung MH, Tien YC, Chiu YM. Risk factors for losing hepatitis B virus surface antibody in patients with HBV surface antigen negative/surface antibody positive serostatus receiving biologic disease-modifying anti-rheumatic drugs: a nested case-control study. Adv Rheumatol 2021;61:22. [PMID: 33832541 DOI: 10.1186/s42358-021-00173-9] [Reference Citation Analysis]
20 Campanati A, Diotallevi F, Martina E, Paolinelli M, Radi G, Offidani A. Safety update of etanercept treatment for moderate to severe plaque psoriasis. Expert Opin Drug Saf 2020;19:439-48. [PMID: 32178543 DOI: 10.1080/14740338.2020.1740204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]